Philately (phil-, philo-loving, fondness for, affinity for; atelia-tax exemption, from Greek) originated as a hobby and business when the first postage stamps appeared in England (1840) with Queen Victoria' s portra it (a one-cent stamp-the "Penny Black").
In clinical trials, using the recommended dose, the overall incidence of adverse events was comparable to vehicle placebo. The most commonly reported adverse events, not necessarily drug related, were, for NASONEX" and vehicle placebo, respectively: headache (17-26% vs 18-22%), viral infection (8-14% vs 9-11%), pharyngitis (10-12% vs 10%), epistaxis/blood-tinged mucus (8-11% vs 6-9%), and coughing (7-13% vs 6-15%).
Note: Controlled clinical studies have shown intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. The growth of pediatric patients receiving intranasal corticosteroids, including NASONEX" Nasal Spray, 50 meg, should be monitored routinely (eg, via stadiometry). The potential of NASONEX" to cause growth suppression in susceptible patients or when given at higher doses cannot be ruled out. Otheradverse events whichoccurred In lessthan5%butgreat erthan or equal to 2% 01 mometasone luroate adult and adolescent patients (ages 12years and older) treated with 200-mcgdoses (regardless 01 relat ionshipto treatment),andmorelrequently thanintheplacebogroup included:arthralgia, asthma, bronchitis, chest pain, conjunctivit is, diarrhea, dyspepsja, earache, flu-like symptoms, myalgia, nausea, and rhinitis.
WWW.NASONEX.COM
Otheradverse events whichoccurredinlessthan 5%but greaterthan or equal10 2%ofmometasone luroatepediatri cpatients ages 3to11 years treated withl 00-mcg doses vspl acebo (re gardless ofrelationshiptotreatment ) andmore frequentlythanin the placebogroupincluded:diarrhea, nasalirritation, otitismedia, andWheezing.
Rare cases ofnasal ulcersand nasal andoral candidiasiswere also report-edinpatientstreatedwithNASONEXNasal Spray,50meg,p r i m a r i~inpatients treatedlorlongerthan 4weeks.
Inpostmarkeling surveillance of thisproduct, cases ofnasal burningand irritation, anaphylaxis andangioedema, and rarecases ofnasal septa l perforation havebeen reported. OVERDOSAGE Ther eare no dataavailable onthe effects ofacute orchronic overdosage with NASONEX Nasal Spray, 50 meg.Because 01 low systemic bioavailability , and an absence ofacutedrug-related systemic fIndings in clinicalstudies, overdose isunlikelytorequireany therapy otherthanobservation. Intranasal administration of1600 meg (8times therecommended dose ofNASONEX Nasal Spray, 50meg) dail ylor29days, tohealthyhuman volunteers,was well toleratedwithno increasedin cidenceofadverse events. Single intranasal doses up to 4000 meg havebeen studied inhuman volunteers with noadverse effectsreport ed.Singleoral dosesupto8000 meg have been studiedinhuman volunteers withno adverse effects report ed. Chronic overdosage with any corticosteroidmay result in signs or symptoms of hypercorticism (see PRECAUTiONS).Acute overdosage withthis dosage formisunlikely since one bottle 01 NASONEX Nasal Spray, 50 meg containsapproximately 8500 mcgofmometasone furoat e. Sevenhundred and h'"nty(720) patients 3to 11 years01 age wer etreated wi thmometasone luroalenasal spray, 50meg (100 meg total da i~dose) in controlled clinical trials. Safety and effectiveness inchildren lessthan3years 01 age have not been established.
Aclinicai study has been conducled tor 1 year in pediatric patients (ages 3109years) toassess theeffect ofNASONEX Nasai Spray, 50meg (100 meg total da ilydose) ongrol 'h velocity. Nostatisticallysignilicanteffect ong r"~h veloci tywas observed lorNASONEX Nasal Spray, 50meg comparedtoplacebo. Noevidenceofcl in icallyrelevant HPAaxis suppression was observed fol-lowinga3D-minute Cosyntropininfusion.
Thepotential 01 NASONEX Nasal Spray, 50meg tocause gro \ '~h suppressi on insusceptiblepatients orwhen given athigher doses cannotberuled out.
Geriatric Use: A total 01 203 patients above 64years of age (age range 64to85years) havebeen treated wi thNASONEX Nasal Spray, 50meg for up to3 months. Theadverse reactionsreported inthispopulation were similar in type andincidence tothose reporte d byyounger patients. ADVERSE REACTIONS Incontrolled USand Internationalclinical studies , a total of3210adull and adotescent patients ages 12years an d older received treatment wi thNASONEX Nasal Spray, 50meg atdoses ot50to800 meg/day. The majority 01 patients (n : 21 03) were treated with 200 meg/day. Incontrolled USand Inlernationalstudies, atotal 01990 pediatric patients (ages 3to 11years) received treatment wit hNASONEX Nasal Spray, 50meg, atdoses 01 25to200meg/ day. Themajority ofpediatri c patients (720) were treatedwit h 100meg/day.Atotal 01 513adul!, adolescent,and pediatricpatientshave been treated for1yearorlonger .The overall incidenceofadverse events forpatients treatedwithNASONEX Nasal Spray, 50megwascomparable topatients treated wi ththe vehicle placebo. AJso, adverse events di d notdiffer significantiy based onage,sex,orrace.Threepercent orless of patients inclini cal trialsdiscontinued treatment because of adverse events; thisratewassimilar for the vehi cleandac tive comparators.
All adverse events (regardless 01relationshiptotreatmenl) reported by5% ormore ofadultand adolescent patients ages 12years and olderwho received NASONEX Nasal Spray, 50meg, 200meg/day an d bypediatr icpatients ages 3to11years who received NASONEX Nasal Spray, 50meg, 100meg/day in clinical trialsvspl acebo and thai were more common with NASONEXNasal Spray, 50meg than pl acebo,are displ ayed inthetabl ebelow.
ADVERSE EVENTS FROM CDNTRO!,LED CLINICAL TRIALS INSEASONAL ALLERGICAND PERENNIAL ALLERGIC RHINITIS (PERCENT OFPATIENTS REPO RTING)
Rev. 2101 20109882T-J8S Copyright © 1997 , 1998 , 1999 Corporation. Allrights reserved. one single-dose, parallel-group study ofpatents inanoutdoor "park"setting (park stu dy) and one environmentai exposure un it (EEU)study an d wi thi n 2days anerthe first dose intwo randomized,double-blind, placebo-controlled, parallel-group seasonal allergic rhinitis studies. Maximum benefit isusually achieved wit hin1to 2weeks afterinitiat ion ofdosing. Patients shouldtake the medicationasdirected and should nol increase theprescribed dosage byusing itmore than once a dayinan attempt to increaseitseffectiveness. Patients should contact their physician ifsymptoms do not improve, or if the condition worsens. To assure proper use of this nasal spray, and to attain maximum benef it, patients shouid readand followthe accompanyingPatient's Inslruclions lorUse carel u l~.
Patients should be cauiioned nottospray NASONEX Nasal Spray, 50meg
intothe eyes or di rect~onto Ihe nasal septum. Personswhoare on immunosuppressantdoses ofcorticosteroids shoul dbe warnedtoavoid exposure tochickenpoxormeasles,and patients shouldalso beadvised that if they are exposed, medical ad~ce shouid besought without delay.
Carci nogenesis, Muta genesi s,l mpairmenl 01 Fertility :Ina2-yearcarcinogenicitystudy of Sprague Dawley rats, mometasone luroatedemostraled no statistically significant increase oftumors atinhalation doses upto67mcglkg (approximately 3 and 2 times the maximum recommended daily intranasal dose inaduitsand children, respectiveiy, ona mcg/m' basis). Ina19-month carcinogenicity studyofSwiss CO-1 mice,mometasone furoate demonstrate d no statisticallysignificantincrease in the incidence of tumors atinhala tion doses upto160mcglkg (approxi mate~4 and 3 limes themaximum recommendeddailyintranasal doseinadultsandchildren, respectively , on amcgl m 1 basis).
At cytotoxicdoses, mometa sonefuroateproduced an increaseinchromosome aberrations invitro inChinesehamster ovary-cell cultures inthe nonactivation phase, but not inthe presence ofrat liverS9 fraction. Mometasone furoate was notmutagenic inIhemouse -~mphoma assay and the Salmonellalf. colVmammalian microsome mutation assay, aChinesehamster lung cen(CHL) chromosomal-aberrations assay, an in vivo mouse bone-marrow erythrocyte-micronucleus assay, arat bone-mar rowclastogenicity assay, and themouse mal egerm-cell clastogenicityassay. Mometasoneluroate also di d notinduce unscheduled DNAsynthesis invivoinrathepatocytes.
Inreproductivestudies inrats, impairment of fertility was notproduced by subculaneous doses upto15mcglkg(less thanthe max imumrecommended daily intranasal dose in adults on a mcgl m?basis). However , momet asone fur oate caused prolonged gestation, prolonged and diff icultlabor, reduced offspring survival, and reduced maternal body wei ght ga in at a dose 01 l Smcglk g.
Pregnancy: Teralogenic En ecls: Pregnan cy Calegory C: Mometasone luroatecausedcieh pal ateinmice atsubcutaneousdoses of6{)mcglkgand above (approdrnately 2 times the maximum recommended da ily intranasal dose in adults ona mcg/m' basis).Offspring survival was reduced in the 180mcglkg group(apprndrnately 4times themaximum recommended d a iĩ nt ranasal dose inadults onamcg/m' basis). No su cheffects were observed at 20mcg!kg (less than themaximum recommendeddaily intranasa l dose in adultsonamcg/m' basis).
Inrabbits,mometasone furoatecausedflexed front pawsatatopical dermal dose of 15 0 mcg!kg (approximateiy 14 times the maximum recommended dailyintranasal dose inadults onamcg/m' basis) .
Inrats, mometasone furoate produced umbilical hernia, cleft palate, and delayed ossificational a topical dermal dose of 600 mcglkg (approxi mal e3 0times the maximum recommendeddaily intranasal dose in adults on a mcg/m' basis). At 1200 mcglkg (a pprox i male~60 times the max imum recommended dailyintranasal dose in adults onamcglm?basis), microphthalmia, umbilical hernias,and delayed ossificationwere observedinrat pups.
Inthesedevelopmenta l studies,therewere also reductionsinmaternal body weighlgain and effects on fetai g rOl 'h (lower letal body weights and/or delayed ossification) inmice (6{)and 180mcglkg), rabbits(150mcglkg), and rats (600mcglkg).
inanoral devel opmenlalstudy inrabbits, at700 mcglkg, (ap p rox ima te~70 times the maximumrecommendeddaily intranasal doseinadults on amcglm? basis),increasedinci dencesof resorptionsand malformations, includingcleft palate and/or head malformations (hydrocephaly or domed head) were observed. Pregnancy lailurewas observed in mostrabbils at2800 mcg!kg (a pproximate~27 0times the maximum recommended dai~intranasal dose in adults onamcg/m'basis).
There are no adequate and well -controlled studies in pregnantwomen. NASONEX Nasal Spray, 50meg, like other corticosteroids, should beused during pregnancy only if thepot ential benefits jus tifythepotentialrisk toIhe fetus.Experience withoral cort icosteroids since their introductioninpharmacologic, as-opposed to physioiogic, doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. Inaddit ion, because thereisa natural increaseincorticosteroid production duri ng pregnancy, most women willrequirealower exogenous corticosteroid dose and many will not need cort icost er oidtreatment during pregnancy.
Nonteratogenic Effects: Hypoadrenalism may occur in inf ants born to women receivingcorticosteroids during pregnancy. Such infantsshould be carefully monitored.
Nursing Mothers: It is not known if mometasone furoate is excreted in human milk. Because othercorticosteroids are excreted in human mil k, caution should be usedwhen NASONEX Nasal Spray , 50meg isadminist ered tonursingwomen.
Pediatric Use:Controlled clinical studies have shown intranasal corticosteroids may cause a reductioningrowth velocityinpediatricpatients. This effect has been observed inthe absence 01labor atorye~dence 01hypolhalamic-pituitary-adrenai (HPA) axis suppression, suggesting that growth velocity isa more sensitive indicator ofsystemiccort icost eroid exposure inpediatric patienls than some commonly usedtests01 HPAax isfunction.The long-term effects ofthisreduction ingrowth velocity associatedwith intranasal corticosteroids, inclUding theimpact onfinaladuitheigh!,are unknown.Thepotential for~ca t c h up" growthfollowingdi sconti nuationof treatment withintranasal corticoster oids has not been adequa l e~studied. The gr"~h 01pediatri c patients receiving intranasal corticosteroids, including NASONEX Nasal Spray, 50meg shoul dbemonitoredrou t ine~(eg,~a stadiomelry).Thepotenti al g r Ol '~h effects ofprolonged treatment should be weighed against clinica l benefits obtained and the availability ofsafe and effective noncorticosleroid treatmental ternatives. Tominimize the systemiceffects of intranasal cort icosteroids, inciuding NASONEX Nasai Spray,50meg, each patient should be titrated tohislher lowest effective dose.
NASONEX® (mometasone furoate monohydrate)
Nasal Spray, 50 mcg *
FOR INTRANASAL USE ONLY
' calculated ontheanhydrous basl s BRIEF SUMMARY (For lullPrescri bingInlormalion, see packageinsert.) INDI CATIONSAND USAGE NASONEX Nasal Spray, 50meg isindicated lor the trealmenl 01 the nasal symptoms 01 seasonal aller gi cand perennialallergic rhinitis, inadults and pediatric patients 3 yearsof age and older. NASONEX Nasal Spray, 50meg isindicated lor theprophylaxis 01 the nasai symptoms 01 seasonal allergicrhinitis inadult and adolescent patients12years andolder. In patients with a known seasonal allergen that precipitat es nasal symptoms 01 seasonal allergicrhinitis, initiation01 prophyiax iswi thNASONEX Nasal Spray, 50meg isrecommended 2to4weeks prior totheanticipated start 01 thepollen season. Salety and effectiveness 01 NASONEX Nasal Spray ,50meg inpediatric patientslessthan3years 01 age ha venotbeenestablished. CO NTRAINDICATIONS Hypersensitivitytoanyotlhe ingredients olthis preparation contraindicales itsuse.
WARNINGS The replacement ot a systemic corticosteroid with a topicai corticosteroid can be accompanied by si gnsofadr enal insufficiency and, in addition, some patients may experience symptoms ofwithdrawal; ie, joint and/or muscular pain, lassitude, and depression. Gareful attention must be given when patients previouslytreated for prolonged per iodswith systemic corticosteroids are transferredto topicalcorticosteroids, with careful monitoring for acute adrenal insufficiency in responsetostress. Thisisparticular ly important in those patients who have associ ated asthma orotherclinical conditions wheretoo rapidadecrease insystemiccorticosteroiddosingmay cause asevere exacerbation oftheirsymptoms.
Ifrecommendeddoses of intranasalcorticosteroids are exceeded orif indivi dualsare part icular lysensiti ve orpredisposedbyvirt ueofrecent systemic steroid therapy, symptoms ofhypercorticismmay occur, inc luding very rare cases of menstrual irregularities, acneiform lesions, andcushingoidfeatures. Ifsuchchanges occur, topical corticosteroidsshouldbediscontinued slowly, consistent withaccepted proceduresfordiscontinuingoral steroid therapy.
Persons who are on drugs which suppress theimmune system are more susceptible toinfections thanhealthy individuals.Chickenpox andmeasles,lor example, canhave amore serious oreven fatal course innonimmunechildren or adults on corticost eroids.Insuch childrenoradults whohavenothad these diseases, particular care shouldbe taken toavoid exposure. Howthe dose, route, andduration ofcorticosteroid administration affects theriskofdevelo pingadisseminat edinfect ionisnot known. Thecontribution ofthe underlying disease and/or prior corticosteroid treatment to the risk isalso not known. 11 exposed tochickenpox, prophyl axis with vari cell a zoster immune globin (VZIG) may be indicated. Ifexposed tomeasles, prophylaxis withpooled intramuscular immunoglobulin(IG) may be indicated. (See therespectivepackage inserts lor complete VZIG and IG prescribing inlo rmation.) If chickenpox develops, treatmentwithantiviralagents maybeconsidered. PRECAUTIONS General : Intranasal corticosteroids may cause areduclionin grOl 'h velocitywhenadministered to pediatricpatients (see PRECAUTIONS, Pediatri cUsesection).Inclinical studies withNASONEX Nasal Spray,50meg, thedevelopmentoflocali zed infectionsofthenose and pharynx with Candida albi",ns has occurredonly rarely. When such an inlection develops, use ot NASONEX Nasal Spray, 50meg shouldbediscontinued and appropriatelocal orsysternc ther apyinslituted, ilneeded.
Nasal corticosleroidsshould beused wit hcaution, il atall, inpatients with active orquiescenttuberculous infection ofthe respiratorytract.orinuntreated fungal.bacterial, systemic vi ral infections, or ocularherpes simplex.
Rarely , immediat ehypersensitivityreactionsmay occur afterthe intranasal administrationof mometasonefuroatemonohydrate. Extreme rareinstances ofwheezinghave beenreported.
Rareinstancesof nasal septum perforation and increasedintraocular pressu rehave also beenreportedfollow ing the intranasal application otaerosolized corticosteroids. As withany long-termtopical treatment ofthe nasal caVity, patienlsusing NASONEX Nasal Spray, 50 meg over several months orlonger shouldbeexamined periodically lor possibl echanges inthenasal mucosa. Becauseofthe inhibitory effect ofcorticosteroids onwound healing,patients who have experienced recentnasal septum ulcers,nasal surgery,ornasalfraurnashouldnotuse anasal corticosteroid untilheali nghas occurred.
Glaucoma andcataract formationwasevaluated inone controlledstudy of 12 weeks' durat ionandone unc ontrolled study of 12months' duration in patienls treated with NASONEX Nasal Spray, 50 meg at200 mcwday, using intraocular pressure measurementsand slitlamp examination. No significant change from baseline wasnoted in the mean intraocular pressure measurementsfor the 141 NASONEX-treated patients inthe 12-week sl udY, ascompared with 141 pl acebo-treated patients. No i n d i~d u a l NASONEX-treated patient was noted tohavedevelopedasignificantelevation inintraocularpressure or cataracts inthis12-weekstudy. Li ke\ 'se , no significant change from baseline was noted inthemeanintraocular pressure measurementsforthe 139 NASONEX-treated patients inthe12-month studyand again, nocataracts were detectedinthese patients. Nonetheless,nasal andinhaledcorticosteroids have been associated with the development ofglaucoma and/orcataracts. Therefore,close foll ow-up iswarranted inpatientswith achangeinvi sionand wit hahistory ofglaucoma and/or cataracts.
Whennasal corticosteroids are used at excessive doses, systemic corticosteroid effectssuch as hypercorticism andadrenal suppression mayappear. If such changes occur, NASONEX Nasai Spray, 50meg should be discontinued slowly, consistent with accepted procedures for discont inuing oral steroid Iherapy.
Information for Patients: Patientsbeing trealedwithNASONEXNasal Spray, 50mcgshould be given the following informati on and instructions.Thisinformation isintendedtoaid inthe safe and effective useof thismedication. Itis notadisclosure ofall intended orpossible adverse effects.Patients shoulduse NASONEX Nasal Spray,50meg atregUlar intervals (once daily) sinceitseffectiveness depends on regular use. Improvement innasal symptoms of allergic rhinitishas beenshowntooccur within 11 hours after the first dose based on Medical philately is one of many forms illustra ting medicin e in history (old and rece nt). Some argue that it' s a hobb y that will be edged out by nonstamp (elec tro nic, Internet , etc.) co mmunication systems. Personal issues might still requi re an envelope with a stamp, however. Moreover , the great majority of the world's inh abitants do not have Internet access, but they do have a local post office and will co ntinue to use the mail for communicating. Th at might be bad news for technology advances, but it' s goo d for "hobby preservation."
The stamps show n here are in no particular order of import ance.
